Viewing Study NCT02299505

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:11 AM
Ignite Modification Date: 2026-02-24 @ 10:55 AM
Study NCT ID: NCT02299505
Status: COMPLETED
Last Update Posted: 2022-02-09
First Post: 2014-11-14
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None LDK378 View
None ceritinib View
None Alk+ View
None Alk positive View
None NSCLC View
None lung Cancer View